The research progress of biologics in elderly-onset rheumatoid arthritis (EORA)
Elderly-onset rheumatoid arthritis (EORA) is a distinct subtype of rheumatoid arthritis characterized by heightened treatment challenges due to immune aging and the complexity of comorbidities. This review systematically summarizes the definition, clinical features, epidemiological trends, therapeut...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Aging |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fragi.2024.1511812/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832590922866491392 |
|---|---|
| author | Yujie Li Yifan Liu Yanhui Tian Huimin Gu Qingliang Meng Jiakang Cui Junfu Ma |
| author_facet | Yujie Li Yifan Liu Yanhui Tian Huimin Gu Qingliang Meng Jiakang Cui Junfu Ma |
| author_sort | Yujie Li |
| collection | DOAJ |
| description | Elderly-onset rheumatoid arthritis (EORA) is a distinct subtype of rheumatoid arthritis characterized by heightened treatment challenges due to immune aging and the complexity of comorbidities. This review systematically summarizes the definition, clinical features, epidemiological trends, therapeutic challenges, and the potential applications of biologic agents in EORA. It primarily focuses on the efficacy, safety, and individualized treatment strategies associated with various biologic agents. Studies indicate that biologics, such as TNF-α inhibitors, IL-6 inhibitors, and JAK inhibitors, can significantly reduce inflammation and improve joint function in EORA patients. However, their long-term use is closely linked to increased risks of infections, thrombosis, and malignancies, underscoring the importance of personalized treatment approaches and dynamic monitoring. Moreover, the advent of novel biologic agents, including IL-17 and IL-23 inhibitors, as well as second-generation JAK inhibitors, offers additional therapeutic options for refractory patients and demonstrates substantial potential in optimizing both efficacy and safety. With the rapid progress of precision medicine and artificial intelligence (AI) technologies, gene profiling, biomarker analysis, and AI-assisted decision-making are gradually steering EORA treatment towards more personalized and precise strategies. However, the high cost of treatment and the limited accessibility of these technologies remain significant barriers in clinical practice. Future research should focus on validating the long-term safety of novel therapies and refining individualized treatment strategies to enhance patient outcomes and quality of life. |
| format | Article |
| id | doaj-art-e4c4b5ecb3f64d5cb898aecf51864c2b |
| institution | Kabale University |
| issn | 2673-6217 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Aging |
| spelling | doaj-art-e4c4b5ecb3f64d5cb898aecf51864c2b2025-01-23T06:56:06ZengFrontiers Media S.A.Frontiers in Aging2673-62172025-01-01510.3389/fragi.2024.15118121511812The research progress of biologics in elderly-onset rheumatoid arthritis (EORA)Yujie Li0Yifan Liu1Yanhui Tian2Huimin Gu3Qingliang Meng4Jiakang Cui5Junfu Ma6College of Orthopedics and Traumatology, Henan University of Chinese Medicine, Zhengzhou, ChinaCollege of Orthopedics and Traumatology, Henan University of Chinese Medicine, Zhengzhou, ChinaCollege of Orthopedics and Traumatology, Henan University of Chinese Medicine, Zhengzhou, ChinaDepartment of Rheumatology, Henan Province Hospital of Traditional Chinese Medicine, Zhengzhou, Henan Province, ChinaDepartment of Rheumatology, Henan Province Hospital of Traditional Chinese Medicine, Zhengzhou, Henan Province, ChinaDepartment of Rheumatology, Henan Province Hospital of Traditional Chinese Medicine, Zhengzhou, Henan Province, ChinaDepartment of Rheumatology, Henan Province Hospital of Traditional Chinese Medicine, Zhengzhou, Henan Province, ChinaElderly-onset rheumatoid arthritis (EORA) is a distinct subtype of rheumatoid arthritis characterized by heightened treatment challenges due to immune aging and the complexity of comorbidities. This review systematically summarizes the definition, clinical features, epidemiological trends, therapeutic challenges, and the potential applications of biologic agents in EORA. It primarily focuses on the efficacy, safety, and individualized treatment strategies associated with various biologic agents. Studies indicate that biologics, such as TNF-α inhibitors, IL-6 inhibitors, and JAK inhibitors, can significantly reduce inflammation and improve joint function in EORA patients. However, their long-term use is closely linked to increased risks of infections, thrombosis, and malignancies, underscoring the importance of personalized treatment approaches and dynamic monitoring. Moreover, the advent of novel biologic agents, including IL-17 and IL-23 inhibitors, as well as second-generation JAK inhibitors, offers additional therapeutic options for refractory patients and demonstrates substantial potential in optimizing both efficacy and safety. With the rapid progress of precision medicine and artificial intelligence (AI) technologies, gene profiling, biomarker analysis, and AI-assisted decision-making are gradually steering EORA treatment towards more personalized and precise strategies. However, the high cost of treatment and the limited accessibility of these technologies remain significant barriers in clinical practice. Future research should focus on validating the long-term safety of novel therapies and refining individualized treatment strategies to enhance patient outcomes and quality of life.https://www.frontiersin.org/articles/10.3389/fragi.2024.1511812/fullelderly-onset rheumatoid arthritisbiologic agentsinfectionindividualized treatmentreview |
| spellingShingle | Yujie Li Yifan Liu Yanhui Tian Huimin Gu Qingliang Meng Jiakang Cui Junfu Ma The research progress of biologics in elderly-onset rheumatoid arthritis (EORA) Frontiers in Aging elderly-onset rheumatoid arthritis biologic agents infection individualized treatment review |
| title | The research progress of biologics in elderly-onset rheumatoid arthritis (EORA) |
| title_full | The research progress of biologics in elderly-onset rheumatoid arthritis (EORA) |
| title_fullStr | The research progress of biologics in elderly-onset rheumatoid arthritis (EORA) |
| title_full_unstemmed | The research progress of biologics in elderly-onset rheumatoid arthritis (EORA) |
| title_short | The research progress of biologics in elderly-onset rheumatoid arthritis (EORA) |
| title_sort | research progress of biologics in elderly onset rheumatoid arthritis eora |
| topic | elderly-onset rheumatoid arthritis biologic agents infection individualized treatment review |
| url | https://www.frontiersin.org/articles/10.3389/fragi.2024.1511812/full |
| work_keys_str_mv | AT yujieli theresearchprogressofbiologicsinelderlyonsetrheumatoidarthritiseora AT yifanliu theresearchprogressofbiologicsinelderlyonsetrheumatoidarthritiseora AT yanhuitian theresearchprogressofbiologicsinelderlyonsetrheumatoidarthritiseora AT huimingu theresearchprogressofbiologicsinelderlyonsetrheumatoidarthritiseora AT qingliangmeng theresearchprogressofbiologicsinelderlyonsetrheumatoidarthritiseora AT jiakangcui theresearchprogressofbiologicsinelderlyonsetrheumatoidarthritiseora AT junfuma theresearchprogressofbiologicsinelderlyonsetrheumatoidarthritiseora AT yujieli researchprogressofbiologicsinelderlyonsetrheumatoidarthritiseora AT yifanliu researchprogressofbiologicsinelderlyonsetrheumatoidarthritiseora AT yanhuitian researchprogressofbiologicsinelderlyonsetrheumatoidarthritiseora AT huimingu researchprogressofbiologicsinelderlyonsetrheumatoidarthritiseora AT qingliangmeng researchprogressofbiologicsinelderlyonsetrheumatoidarthritiseora AT jiakangcui researchprogressofbiologicsinelderlyonsetrheumatoidarthritiseora AT junfuma researchprogressofbiologicsinelderlyonsetrheumatoidarthritiseora |